EW

Edwards Lifesciences Corp
NYSE
89.50
-1.49
-1.64%
After Hours: 89.50 0 0.00% 16:41 07/15 EDT
OPEN
91.49
PREV CLOSE
90.99
HIGH
91.49
LOW
88.90
VOLUME
3.05M
TURNOVER
0
52 WEEK HIGH
96.12
52 WEEK LOW
60.57
MARKET CAP
53.93B
P/E (TTM)
38.47
1D
5D
1M
3M
1Y
5Y
1D
Sector Update: Health Care Stocks Retreat Monday Afternoon
NASDAQ · 6h ago
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
NASDAQ · 9h ago
Validea Detailed Fundamental Analysis - EW
NASDAQ · 10h ago
Edwards Lifesciences to Buy Innovalve for $300M
Dow Jones · 10h ago
Edwards Lifesciences Expands with Innovalve Acquisition Deal
TipRanks · 10h ago
Edwards Lifesciences acquires early-stage TMVR company Innovalve
M&A Edwards Lifesciences acquires early-stage TMVR company Innovalve. The terms of the deal were not disclosed. The acquisition is expected to close by the end of 2024. Edwards Lifsciences (EW) has acquired InnovalVE Bio Medical Ltd.
Seeking Alpha · 10h ago
Edwards Lifesciences To Acquire Innovalve Bio Medical Ltd., Acquisition Is Expected To Close By The End Of 2024; No Financial Terms Disclosed
Edwards Lifesciences exercises its option to acquire Innovalve Bio Medical Ltd. The company is an early-stage transcatheter mitral valve replacement company. The acquisition will help address large unmet structural heart patient needs. Inovalve will join Edwards' mitral and tricuspid therapies product group.
Benzinga · 11h ago
*Edwards Lifesciences: SAPIEN M3 Remains on Track to Become First Approved Transfemoral TMVR System in Europe by End of 2025 >EW
Dow Jones · 11h ago
More
About EW
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions.

Webull offers Edwards Lifesciences Corp stock information, including NYSE: EW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EW stock methods without spending real money on the virtual paper trading platform.